Decreased Expression of Inhibitor of Caspase-Activated DNase (ICAD) in Renal Cell Carcinoma – Tissue Microarray of Human Samples

Although primary localised tumours of renal cell carcinoma (RCC) can be treated relatively successfully with surgery, metastatic RCC has poor prognosis because of late diagnosis and resistance to therapies. In the present study, we were interested in profiling the protein expression of “inhibitor of caspase-activated DNase” (ICAD), an apoptosis inhibitor, in kidney cancer and its paired normal kidney. Immunohistochemistry with automated batch staining and morphometry using digital pathology were used to compare ICAD in 121 RCC specimens with their paired normal kidney tissue. Tissue microarray of formalin-fixed, paraffin-embedded archival tissue was used. Intensity and localisation of ICAD were compared between normal and cancer samples, and against grading within the cancers. The results demonstrated that, in this cohort, ICAD was highly expressed in the proximal tubular epithelium of normal kidney, and significantly decreased in clear cell RCC tissue (p < 0.05) as well as other subtypes of RCC (p < 0.01) compared with normal kidney. There was a tendency towards nuclear localisation of ICAD in clear cell RCC, but not in other subtypes of RCC. No significant association was found between ICAD intensity and grade of RCC. In summary, down-regulation of ICAD occurs in RCC. ICAD normally inhibits DNA fragmentation and apoptosis; thus, its down-regulation was unexpected in a cancer known for its resistance to apoptosis. However, these RCC samples were from primary, not metastatic, RCC sites, and down-regulated ICAD may be part of a progressive pathway that promotes RCC metastasis.

[1]  S. S. Boon,et al.  Inhibitor of caspase-activated DNase expression enhances caspase-activated DNase expression and inhibits oxidative stress-induced chromosome breaks at the mixed lineage leukaemia gene in nasopharyngeal carcinoma cells , 2015, Cancer Cell International.

[2]  A. Basnakian,et al.  Regulation of Apoptotic Endonucleases by EndoG. , 2015, DNA and cell biology.

[3]  J. Cheville,et al.  [Renal tumors: The International Society of Urologic Pathology (ISUP) 2012 consensus conference recommendations]. , 2014, Annales de pathologie.

[4]  H. Samaratunga,et al.  Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem? , 2013, Journal of Clinical Pathology.

[5]  David W. Johnson,et al.  Patient samples of renal cell carcinoma show reduced expression of TRAF1 compared with normal kidney and functional studies in vitro indicate TRAF1 promotes apoptosis: potential for targeted therapy , 2012, Pathology.

[6]  Han Yong Choi,et al.  The epidemiology of renal cell carcinoma. , 2011, European urology.

[7]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[8]  David W. Johnson,et al.  Expression of apoptotic tumour necrosis factor receptor‐associated factor, caspase recruitment domain and cell death‐inducing DFF‐45 effector genes in therapy‐treated renal cell carcinoma , 2009, Nephrology.

[9]  M. Delivoria-Papadopoulos,et al.  Mechanism of DNA Fragmentation During Hypoxia in the Cerebral Cortex of Newborn Piglets , 2008, Neurochemical Research.

[10]  D. Rimm,et al.  Vascular endothelial growth factor, FLT‐1, and FLK‐1 analysis in a pancreatic cancer tissue microarray , 2006, Cancer.

[11]  M. Amin,et al.  An immunohistochemical approach to the differential diagnosis of renal tumors. , 2005, Seminars in diagnostic pathology.

[12]  D. Ornstein.  Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs , 2004 .

[13]  V. Speirs,et al.  Tissue microarrays--big potential from small samples (review). , 2004, International journal of oncology.

[14]  D. Gilot,et al.  The Hepatitis C Virus NS2 Protein Is an Inhibitor of CIDE-B-induced Apoptosis* , 2003, The Journal of Biological Chemistry.

[15]  D. Rimm,et al.  Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.

[16]  A. Pingoud,et al.  The effect of ICAD-S on the formation and intracellular distribution of a nucleolytically active caspase-activated DNase. , 2002, Nucleic Acids Research.

[17]  M. Denis,et al.  Growth phase-dependent expression of ICAD-L/DFF45 modulates the pattern of apoptosis in human colonic cancer cells. , 2002, Cancer research.

[18]  H. Miyake,et al.  Over expression of inhibitor of caspase 3 activated deoxyribonuclease in human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy in vivo. , 2001, The Journal of urology.

[19]  T. Shiraishi,et al.  Expression of ICAD‐L and ICAD‐S in Human Brain Tumor and Its Cleavage upon Activation of Apoptosis by Anti‐Fas Antibody , 2001, Japanese journal of cancer research : Gann.

[20]  E. Devilard,et al.  Frequent nuclear localization of ICAD and cytoplasmic co‐expression of caspase‐8 and caspase‐3 in human lymphomas , 2000, The Journal of pathology.

[21]  E. Petricoin,et al.  Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines , 2000, Electrophoresis.

[22]  S. Nagata.  Apoptotic DNA fragmentation. , 2000, Experimental cell research.

[23]  M. Emmert-Buck,et al.  Layered expression scanning: rapid molecular profiling of tumor samples. , 2000, Cancer research.

[24]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[25]  W. Earnshaw,et al.  ICAD/DFF regulator of apoptotic nuclease is nuclear. , 1998, Experimental cell research.

[26]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[27]  S. Chen,et al.  CIDE, a novel family of cell death activators with homology to the 45 kDa subunit of the DNA fragmentation factor , 1998, The EMBO journal.

[28]  Jonathan I. Epstein,et al.  WHO Classification of of Tumours of the Urinary System and Male Genital Organs , 2016 .

[29]  S. Nagata,et al.  Nucleases in programmed cell death. , 2008, Methods in enzymology.

[30]  S. Nagata.  DNA degradation in development and programmed cell death. , 2005, Annual review of immunology.

[31]  R. Amato.  Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  S. Nagata,et al.  Degradation of chromosomal DNA during apoptosis , 2003, Cell Death and Differentiation.